Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation

European Journal of Clinical Pharmacology

Volumn 70, Issue 11, 2014, Pages 1339-1351

  Yin, Ophelia Q P ^a   Tetsuya, Kimura ^b   Miller, Raymond ^a  

^a DAIICHI SANKYO INC   (United States)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Edoxaban; Exposure response; Population pharmacokinetics

Indexed keywords

AMIODARONE; EDOXABAN; ERYTHROMYCIN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; QUINIDINE; VERAPAMIL; ANTICOAGULANT AGENT; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NON VALVULAR ATRIAL FIBRILLATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BIOAVAILABILITY; BIOLOGICAL MODEL; BLEEDING; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; KIDNEY FAILURE; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PYRIDINES; QUINIDINE; RENAL INSUFFICIENCY; THIAZOLES; YOUNG ADULT;

EID: 84919768868     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1736-4     Document Type: Article

References (32)

1. Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T (2008) DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 6:1542-1549
2. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI (2010) Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 104:642-649
3. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633-641
4. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 160:635-641
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093-2104
6. The Hokusai-VTE Investigators (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406-1415
7. Matsushima N, Lee F, Sato T, Weiss D, Mendell J (2013) Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin Pharmacol Drug Dev 2:358-366
8. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743-753
9. Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 40:2250-2255
10. Masumoto H, Yoshigae Y, Watanabe K, Takakusa H, Okazaki O, Izumi T (2010) In vitro metabolism of edoxaban and the enzymes involved in the oxidative metabolism of edoxaban. AAPS J S2:Abstract W4308
11. Mendell JJL, Ridout G, He L, Chen S (2012) An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics. Eur Heart J 33(Suppl 1):Abstract 2024
12. Graff J, Harder S (2013) Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 52:243-254
13. Mikkaichi T, Yoshigae Y, Masumoto H, Imaoka T, Rozehnal V, Fischer T, Okudaira N, Izumi T (2014) Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos 42:520-528
14. Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, Zhang G, Shi M (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331-342
15. Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107:925-936
16. Ridout G, de lat Motte S, Sramek P, Johnson L, Ling H, Mendell J, Salazar D (2009) Effect of renal function on edoxaban pharmacokinetics and on population PK/PD model. J Clin Pharmacol 49:1124
17. Parasrampuria D, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown K (2013) Safety, tolerability, and pharmacokinetics of edoxaban in end-stage renal disease subjects undergoing hemodialysis. J Thromb Haemost 11:255-256
18. Fuji T, Fujita S, Abe Y, Tachibana S, Kawai Y (2013) Evaluation of edoxaban in Japanese patients with severe renal impairment undergoing lower-limb orthopedic surgery. J Thromb Haemost 11:556-557
19. Koretsune Y, Yamashita T, Yasaka M (2013) Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment. Eur Heart J 34:95
20. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
21. Beal SL, Sheiner LB (1998) NONMEM users' guide. NONMEM Project Group, University of California at San Francisco, San Francisco
22. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed 58:51-64
23. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit - a collection of computer intensive statistical methods for non-linear mixed effect modeling using NON MEM. Comput Methods Prog Biomed 79:241-257
24. Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75:85-94
25. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic - pharmacodynamic models. I. Models covariate effects. J Pharmacokinet Biopharm 20:511-528
26. Ananth CV, Kleinbaum DG (1997) Regression models for ordinal responses: a review of methods and applications. Int J Epidemiol 26:1323-1233
27. Grover A, Benet LZ (2009) Effects of drug transporters on volume of distribution. AAPS J 11:250-261
28. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236
29. Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18:157-169
30. Lip GY, Larsen TB, Skjøth F, Rasmussen LH (2012) Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60:738-746
31. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, Breithardt G, Fox KA, Califf RM, Investigators ROCKETAF (2014) Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 63:891-900
32. Hughes M, Lip GY, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2007) Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. Q J Med 100:599-607